These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28174600)

  • 1. Does accreditation improve pro re nata benzodiazepines administration in psychiatric inpatients? Pre-post accreditation medical record comparison.
    Al-Sughayir MA
    Int J Ment Health Syst; 2017; 11():16. PubMed ID: 28174600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administered antipsychotic pro re nata medications in psychiatric inpatients. Pre- and post-accreditation comparison.
    Al-Sughayir MA
    Saudi Med J; 2014 Feb; 35(2):172-7. PubMed ID: 24562517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of accreditation on length of stay in psychiatric inpatients: pre-post accreditation medical record comparison.
    Al-Sughayir MA
    Int J Ment Health Syst; 2016; 10(1):55. PubMed ID: 27606002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals.
    Geffen J; Sorensen L; Stokes J; Cameron A; Roberts MS; Geffen L
    Aust N Z J Psychiatry; 2002 Oct; 36(5):649-56. PubMed ID: 12225449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of pro re nata medications in acute inpatient care.
    Stein-Parbury J; Reid K; Smith N; Mouhanna D; Lamont F
    Aust N Z J Psychiatry; 2008 Apr; 42(4):283-92. PubMed ID: 18330770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Descriptive analysis of pro re nata medication use at a Canadian psychiatric hospital.
    Martin K; Arora V; Fischler I; Tremblay R
    Int J Ment Health Nurs; 2017 Aug; 26(4):402-408. PubMed ID: 27804222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.
    Davies SJ; Lennard MS; Ghahramani P; Pratt P; Robertson A; Potokar J
    J Psychopharmacol; 2007 Mar; 21(2):153-60. PubMed ID: 17329294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro re nata medication for psychoses: the knowledge and beliefs of doctors and nurses.
    Geffen J; Cameron A; Sorensen L; Stokes J; Roberts MS; Geffen L
    Aust N Z J Psychiatry; 2002 Oct; 36(5):642-8. PubMed ID: 12225448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Psychotropic PRN Medications in a Canadian Psychiatric Intensive Care Unit.
    Casol M; Tong A; Ng JCY; McGloin R
    J Am Psychiatr Nurses Assoc; 2023; 29(2):103-111. PubMed ID: 34109871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro re nata medication for psychiatric inpatients: time to act.
    Hilton MF; Whiteford HA
    Aust N Z J Psychiatry; 2008 Jul; 42(7):555-64. PubMed ID: 18612858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of PRN Medication Administration in Australian Residential Aged Care.
    Picton L; Ilomäki J; Keen CS; Lalic S; Adams B; Clinnick LM; Kirkpatrick CM; Ryan-Atwood T; Turner JP; Bell JS
    J Am Med Dir Assoc; 2021 Jan; 22(1):117-123.e1. PubMed ID: 32611523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A best-evidence synthesis review of the administration of psychotropic pro re nata (PRN) medication in in-patient mental health settings.
    Baker JA; Lovell K; Harris N
    J Clin Nurs; 2008 May; 17(9):1122-31. PubMed ID: 18416789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a Novel Standardized Administration Protocol Reduces Agitation Pro Re Nata (PRN) Medication Requirements: The Birmingham Agitation Management (BAM) Initiative.
    Burk BG; Penherski P; Snider K; Lewellyn L; Mattox L; Polancich S; Fargason R; Waggoner B; Caine E; Hand W; Eagleson RM; Birur B
    Ann Pharmacother; 2023 Apr; 57(4):397-407. PubMed ID: 35950625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro re nata prescribing and administration for neuropsychiatric symptoms and pain in long-term care residents with dementia and memory problems: a cross-sectional study.
    Griffiths AW; Surr CA; Alldred DP; Baker J; Higham R; Spilsbury K; Thompson CA
    Int J Clin Pharm; 2019 Oct; 41(5):1314-1322. PubMed ID: 31342248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Documentation of psychotropic pro re nata medication administration: An evaluation of electronic health records compared with paper charts and verbal reports.
    Martin K; Ham E; Hilton NZ
    J Clin Nurs; 2018 Aug; 27(15-16):3171-3178. PubMed ID: 29752835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing utilization of pro re nata ('as needed') sedation in a child and adolescent psychiatric inpatient unit.
    Dean AJ; Scott J; McDermott BM
    Aust N Z J Psychiatry; 2009 Apr; 43(4):360-5. PubMed ID: 19296292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient participation in pro re nata medication in psychiatric inpatient settings: An integrative review.
    Hipp K; Kuosmanen L; Repo-Tiihonen E; Leinonen M; Louheranta O; Kangasniemi M
    Int J Ment Health Nurs; 2018 Apr; 27(2):536-554. PubMed ID: 29271033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Administration of
    Jimu M; Doyle L
    Issues Ment Health Nurs; 2019 Jun; 40(6):511-517. PubMed ID: 30917088
    [No Abstract]   [Full Text] [Related]  

  • 19. Pro re nata medications in mental health: Results of a transversal study.
    Legrand G; Gregoire E; Fererol D; Cardinaud Z; Cussac-Buchdahl C; Debost-Legrand A
    Encephale; 2023 Jun; 49(3):268-274. PubMed ID: 36253181
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Saito E; Eng S; Grosso C; Ozinci Z; Van Meter A
    J Child Adolesc Psychopharmacol; 2020 May; 30(4):250-260. PubMed ID: 31800304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.